The right targeted treatment depends on your tumour’s type, location, stage, biomarker result, previous treatment and overall health—not simply on having a mutation or living in Pune. By the end, you will know which test results matter, how to compare treatment choices, and what to ask an oncologist before starting therapy.
Key takeaways
- Confirm cancer type, stage, pathology and treatment goal before choosing therapy.
- Match treatment to a validated biomarker from the correct tumour specimen.
- Ask how targeted therapy fits with surgery, radiation, chemotherapy or immunotherapy.
- Discuss response checks, side effects, cost, duration and the plan if treatment stops working.
What must be known before choosing a targeted treatment?
The team first confirms the cancer type, primary site, stage, spread pattern, pathology, treatment goal and previous therapies. A newly diagnosed localised cancer may need surgery or radiation before systemic treatment; metastatic disease needs a plan for disease control, symptom relief and long-term sequencing.
Searching “which targeted therapy for fits your cancer in Pune” does not answer that decision: the tumour’s biomarker profile usually matters more than the city, stage alone or preference.
Before naming a drug, the oncologist checks:
- Whether the alteration is clinically actionable for that tumour type, supported by evidence or an approved indication, and suitable after reviewing kidney and liver function, performance status, drug interactions and patient risks.
- Whether hormone-receptor status supports hormone-directed treatment. PD-L1 and MSI-H or mismatch-repair deficiency can guide immune-checkpoint treatment, which is immunotherapy rather than conventional molecular targeted therapy.
| Finding | Meaning | Treatment relevance |
|---|---|---|
| Driver mutation | Alteration that fuels tumour growth | May identify a matching drug |
| Inherited mutation | Change present in normal cells | May require germline testing and genetic counselling |
| Resistance mutation | Change acquired during treatment | May explain progression and alter sequencing |
| Prognostic or monitoring marker | Helps estimate outlook or track disease | Does not automatically identify a drug |
A reported mutation is not automatically a target. The result must predict benefit for that cancer, and the overall plan must be safer and more useful than available alternatives.
Which biomarker test and specimen can identify an eligible target?
A biopsy sample, surgical tissue, blood-based liquid biopsy, or repeat specimen can identify an eligible target. A repeat sample matters when the tumour has changed after treatment. Common biomarkers include HER2, EGFR, ALK, ROS1, BRAF, KRAS, BRCA1/2, NTRK, RET, MET, MSI-H, mismatch-repair deficiency, PD-L1 and hormone-receptor status.
| Test | What it examines | When it fits |
|---|---|---|
| Immunohistochemistry | HER2, hormone receptors, mismatch-repair proteins and PD-L1 | Focused testing, such as HER2 in breast cancer |
| Fluorescence in situ hybridisation | HER2 amplification or gene rearrangements | Clarifies an equivocal HER2 result or rearrangement |
| Polymerase chain reaction | Selected mutations | A specific suspected alteration |
| Next-generation sequencing | Many genes in one panel | Advanced disease, rare tumours or several possible targets |
| Liquid biopsy | Circulating tumour DNA in blood | When tissue is unavailable or repeat sampling is difficult |
A focused test is preferable when one result directly determines treatment, such as EGFR testing in non-small-cell lung cancer. Broad next-generation sequencing can find several possible targets when the disease is advanced or uncommon.
A search for targeted therapy options in Pune should begin with the tumour type and the test linked to the proposed drug, not a drug list.
- Positive: the alteration or protein expression meets the assay’s treatment threshold.
- Negative: the assay did not detect it; a negative liquid biopsy does not exclude a target because circulating DNA may be below detection.
- Unknown or insufficient: the result cannot guide treatment until better information or tissue is obtained.
- Variant of uncertain significance: its effect is unproven and it is not evidence that a targeted drug will work.
How do cancer-specific biomarker results change the treatment options?
The same cancer label can produce different drug choices because treatment follows the tumour’s actionable biomarker, not the diagnosis alone. In breast or gastric cancer, HER2-positive disease can support HER2-directed treatment, while HER2-negative disease generally does not benefit from those drugs.
Breast HER2 status is usually established by immunohistochemistry (IHC), with in-situ hybridisation (ISH) when IHC is equivocal or amplification needs clarification.
| Cancer setting | Biomarker result | Treatment implication |
|---|---|---|
| Breast or gastric cancer | HER2-positive | Supports HER2-directed treatment |
| Non-small-cell lung cancer | Sensitising EGFR mutation | EGFR inhibitor |
| Non-small-cell lung cancer | ALK or ROS1 rearrangement | ALK inhibitor or ROS1 inhibitor |
| Non-small-cell lung cancer | BRAF V600 tumour | BRAF/MEK-directed treatment for eligible disease |
| Non-small-cell lung cancer | KRAS G12C disease | KRAS G12C inhibitor for eligible patients |
These are biomarker-specific options, not interchangeable lung-cancer medicines. This distinction shapes targeted cancer treatment choices in Pune as much as elsewhere.
For colorectal cancer, KRAS and NRAS testing comes before EGFR-directed antibodies: RAS-mutated tumours generally do not respond, while selected RAS-wild-type tumours may qualify. BRAF V600E and MSI-H or mismatch-repair-deficient results lead to different treatment routes.
BRCA1/2 or other homologous-recombination findings can support PARP-inhibitor treatment in selected ovarian, breast, pancreatic and prostate cancers. A tumour-only result is different from an inherited finding; genetic counselling and confirmatory germline testing may be needed because inherited results can affect relatives.
When is targeted therapy used, combined or changed?
A biomarker-matched drug can be used at several points, not only after other treatments fail. For advanced cancer, it may be the first-line treatment; after surgery, it may reduce recurrence risk when evidence supports adjuvant use. It can also follow chemotherapy, accompany carefully planned radiation, or replace another targeted drug at progression.
1. Choose the sequence according to diagnosis and evidence. Some plans combine targeted therapy with chemotherapy or immunotherapy, while selected HER2-positive cancers receive dual HER2 blockade. These combinations are not universal: the oncologist must weigh clinical evidence, current approvals in India, expected benefit, overlapping toxicity and your overall condition.
This is why targeted cancer treatment choices in Pune must follow the tumour profile, not location or preference alone.
2. Investigate progression before simply switching drugs. Resistance can result from a new resistance alteration, a bypass pathway, tumour-lineage change or resistant subclones present from the beginning. A repeat tissue biopsy or liquid biopsy can sometimes identify a new target, but either test can be uninformative.
3. Monitor treatment as actively as the tumour. Depending on the drug, checks may cover rash, diarrhoea, blood pressure, urine protein, liver tests, heart function, lung symptoms, bleeding, thrombosis, eye problems or neurological effects. Dose interruption or reduction may be necessary when toxicity becomes unsafe.
What should you ask an oncologist before starting treatment in Pune?
Before consenting, leave the consultation with four answers in writing. The best oncologist for targeted therapy in Pune will connect the report to your complete clinical situation, not select a drug from a gene name alone.
1. Record the exact biomarker and test method: immunohistochemistry, PCR, fluorescence in situ hybridisation, next-generation sequencing or liquid biopsy. Ask whether it is tumour-only or inherited, whether a repeat test is needed, and whether a second pathology or molecular review could change the decision.
2. Ask whether the result is predictive for the proposed drug in your tumour type. A rare alteration or variant of uncertain significance is not proof that treatment will work; a negative liquid biopsy may need confirmation with adequate tissue.
3. Compare expected benefit with alternatives.
| Option | What to compare | Question to ask |
|---|---|---|
| Matched approved drug | Evidence, indication, benefit | What result supports it? |
| Clinical trial | Eligibility, location, added visits | Is a suitable trial available? |
| Off-label treatment | Evidence, uncertainty, cost | Why this option over approved care? |
4. Agree on monitoring: scan timing, response, progression, blood tests and toxicity checks for heart, liver, kidneys, blood pressure, skin, lungs or eyes.
Confirm drug access in Pune, financial planning and prior authorisation requirements; verify a clinical trial rather than trusting an online list. A second opinion matters for rare findings, uncertain variants or off-label treatment.
Dr. Pratik Patil - Best Oncologist in Pune can be one clinician asked to document an evidence-based plan covering stage, prior treatment, performance status, organ function and drug interactions.
Related service
Targeted Therapy What is targeted therapy? Targeted therapy is a type of cancer treatment that targets proteins that influence how cancer cells grow, divide, and... View service → |
Frequently asked questions
What must be known before choosing a targeted treatment?
Your care team needs the cancer type, primary site, stage, spread pattern, pathology, treatment goal and previous therapies. Localised and metastatic cancers can require different treatment sequences.
Which biomarker test and specimen can identify an eligible target?
The test depends on the cancer. Ask whether testing uses a biopsy tissue block, newly collected tissue, blood-based liquid biopsy or another specimen, and confirm that the result identifies a treatment-linked biomarker.
How do biomarker results change cancer treatment options?
A validated biomarker can identify a targeted drug or clinical trial option. A negative, unclear or incomplete result may lead your oncologist to consider chemotherapy, immunotherapy, surgery, radiation or additional testing.
When is targeted therapy used, combined or changed?
Targeted therapy may be used alone or with other treatment according to cancer type, stage, biomarker status, treatment goal and prior therapy. Your oncologist can change it when the cancer progresses, side effects become unsafe or a better-supported option becomes available.
What should you ask an oncologist before starting targeted therapy in Pune?
Ask which biomarker supports the treatment, which specimen was tested, the expected benefit, monitoring schedule, common serious side effects, duration, costs, drug interactions and the next plan if the cancer progresses.
